Literature DB >> 9257797

Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines.

T Kumagai1, T Yamanaka, Y Wataya, A Umetsu, N Kawamura, K Ikeda, H Furukawa, K Kimura, S Chiba, S Saito, N Sugawara, F Kurimoto, M Sakaguchi, S Inouye.   

Abstract

BACKGROUND: This study was designed to investigate the development of both cellular and humoral immune responses to gelatin in patients with vaccine-related immediate and nonimmediate reactions. Our purpose was to define the nature of the responses in the different clinical states.
METHODS: Six patients with immediate reactions and 21 patients with nonimmediate reactions after inoculation of various live vaccines were studied. Measurement of gelatin-specific IgE was performed in all subjects. Gelatin-specific T-cell responses detected by an in vitro lymphocyte proliferation assay and by an assay for IL-2 responsiveness were investigated to compare the immune response in patients with the two types of reaction.
RESULTS: All six patients with immediate reactions had IgE responses to gelatin, whereas none of the 21 patients with nonimmediate reactions had any anti-gelatin IgE. All of the six patients with immediate reactions and 17 of the 21 patients with nonimmediate reactions exhibited positive T-lymphocyte responses specific to gelatin.
CONCLUSIONS: Immediate and nonimmediate reactions are caused by different types of allergy to gelatin, and cell-mediated immunity to gelatin may play an important role in the pathogenesis of nonimmediate reactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9257797     DOI: 10.1016/s0091-6749(97)70204-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

1.  MMR vaccine and allergy.

Authors:  R Lakshman; A Finn
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

2.  Public health: Sustainable development, human induced global climate change, and the health of children.

Authors:  T Waterston; S Lenton
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

3.  Contribution of conformational stability of hen lysozyme to induction of type 2 T-helper immune responses.

Authors:  T So; H Ito; M Hirata; T Ueda; T Imoto
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

4.  Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine.

Authors:  Vladimir Liska; Stacey A Bigert; Philip S Bennett; David Olsen; Robert Chang; Carl J Burke
Journal:  J Immune Based Ther Vaccines       Date:  2007-02-23

5.  Vaccination in children with allergy to non active vaccine components.

Authors:  Fabrizio Franceschini; Paolo Bottau; Silvia Caimmi; Giuseppe Crisafulli; Liotti Lucia; Diego Peroni; Francesca Saretta; Mario Vernich; Carlotta Povesi Dascola; Carlo Caffarelli
Journal:  Clin Transl Med       Date:  2015-02-14

6.  International Consensus (ICON): allergic reactions to vaccines.

Authors:  Stephen C Dreskin; Neal A Halsey; John M Kelso; Robert A Wood; Donna S Hummell; Kathryn M Edwards; Jean-Christoph Caubet; Renata J M Engler; Michael S Gold; Claude Ponvert; Pascal Demoly; Mario Sanchez-Borges; Antonella Muraro; James T Li; Menachem Rottem; Lanny J Rosenwasser
Journal:  World Allergy Organ J       Date:  2016-09-16       Impact factor: 4.084

7.  Immunoblot analysis for IgE-reactive components of fetal calf serum in dogs that developed allergic reactions after non-rabies vaccination.

Authors:  Keitaro Ohmori; Kenichi Masuda; Douglas J DeBoer; Masahiro Sakaguchi; Hajime Tsujimoto
Journal:  Vet Immunol Immunopathol       Date:  2006-11-21       Impact factor: 2.046

Review 8.  Hazardous Medications in Children with Egg, Red Meat, Gelatin, Fish, and Cow's Milk Allergy.

Authors:  Sule Caglayan-Sozmen; Angelica Santoro; Francesca Cipriani; Carla Mastrorilli; Giampaolo Ricci; Carlo Caffarelli
Journal:  Medicina (Kaunas)       Date:  2019-08-19       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.